KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Raw Materials (2016 - 2025)

Ionis Pharmaceuticals has reported Raw Materials over the past 17 years, most recently at $640000.0 for Q1 2025.

  • Quarterly results put Raw Materials at $640000.0 for Q1 2025, down 97.34% from a year ago — trailing twelve months through Mar 2025 was $640000.0 (down 97.34% YoY), and the annual figure for FY2024 was $5.6 million, up 207.02%.
  • Raw Materials for Q1 2025 was $640000.0 at Ionis Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Over the last five years, Raw Materials for IONS hit a ceiling of $24.6 million in Q2 2024 and a floor of $640000.0 in Q1 2025.
  • Median Raw Materials over the past 5 years was $18.6 million (2021), compared with a mean of $17.0 million.
  • Biggest five-year swings in Raw Materials: skyrocketed 207.02% in 2024 and later plummeted 97.34% in 2025.
  • Ionis Pharmaceuticals' Raw Materials stood at $18.6 million in 2021, then grew by 5.97% to $19.8 million in 2022, then crashed by 90.84% to $1.8 million in 2023, then skyrocketed by 207.02% to $5.6 million in 2024, then plummeted by 88.48% to $640000.0 in 2025.
  • The last three reported values for Raw Materials were $640000.0 (Q1 2025), $5.6 million (Q4 2024), and $21.7 million (Q3 2024) per Business Quant data.